Drug Trial Radar · NCT07738679
Clinical Trial Evaluating the Efficacy and Safety of TQB3454 Tablets in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
127
Planned (sponsor's estimate)
Start
Jul 2026
Primary completion
Dec 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter phase II study designed to evaluate the efficacy and safety of TQB3454 as monotherapy in patients with advanced solid tumors, divided into three cohorts.Cohort 1: Enrolled patients with diffuse glioma harbouring IDH1 R132 mutations. Cohort 2: Enrolled patients with advanced solid tumours (excluding glioma) harbouring IDH1 R132 mutations who failed standard therapy. Cohort 3: Enrolled patients with locally advanced, recurrent and/or metastatic biliary tract cancer without IDH1 mutations who progressed after gemcitabine or fluoropyrimidine-based treatment.
Conditions
- Advanced Solid Tumors
Interventions
TQB3454 tabletsDrug
TQB3454 is a selective inhibitor of the IDH1 mutant enzyme.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Control Rate (DCR)Time frame: up to 48 weeks
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Sanbo Brain Hospital,Capital Medical University
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
The Second Hospital & Clinical Medical School, Lanzhou University
Lanzhou, Gansu, China
Sun Yat-Sen Uuniversity Cancer Cerntr
Guangzhou, Guangdong, China
AnYang Tumor Hospital
Anyang, Henan, China
Luoyang Central Hospital (Zhengzhou University Affiliated Luoyang Central Hospital)
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Zhengzhou University First Affiliated Hospital
Zhengzhou, Henan, China
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
Liaoning Tumor Hospital & Institute
Shenyang, Liaoning, China
The First Affiliated Hospital of Xi 'an Jiaotong University Medical College
Xi'an, Shaanxi, China
Shandong Cancer Hosipital
Jinan, Shandong, China
Shanghai Sixth People's Hospital, Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, China
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, China
SiChuan cancer hospital
Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.